Abstract | BACKGROUND: METHODS: RESULTS: During a mean follow-up of 3.9 years, dementia was documented in 193 (6.3%) of the 3051 randomized participants in the actively treated group and 217 (7.1%) of the 3054 randomized participants in the placebo group (relative risk reduction, 12% [95% confidence interval, -8% to 28%]; P =.2). Cognitive decline occurred in 9.1% of the actively treated group and 11.0% of the placebo group (risk reduction, 19% [95% confidence interval, 4% to 32%]; P =.01). The risks of the composite outcomes of dementia with recurrent stroke and of cognitive decline with recurrent stroke were reduced by 34% (95% confidence interval, 3% to 55%) (P =.03) and 45% (95% confidence interval, 21% to 61%) (P<.001), respectively, with no clear effect on either dementia or cognitive decline in the absence of recurrent stroke. CONCLUSIONS:
|
Authors | Christophe Tzourio, Craig Anderson, Neil Chapman, Mark Woodward, Bruce Neal, Stephen MacMahon, John Chalmers, PROGRESS Collaborative Group |
Journal | Archives of internal medicine
(Arch Intern Med)
Vol. 163
Issue 9
Pg. 1069-75
(May 12 2003)
ISSN: 0003-9926 [Print] United States |
PMID | 12742805
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Diuretics
- Indapamide
- Perindopril
|
Topics |
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Antihypertensive Agents
(administration & dosage, therapeutic use)
- Blood Pressure
(drug effects)
- Cerebrovascular Disorders
(complications, etiology)
- Cognition
(drug effects)
- Cognition Disorders
(etiology, prevention & control)
- Dementia
(etiology, prevention & control)
- Diuretics
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Hypertension
(complications, drug therapy)
- Indapamide
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Perindopril
(administration & dosage, therapeutic use)
- Risk
- Treatment Outcome
|